A Single‐Cell Atlas of Juvenile Nasopharyngeal Angiofibroma Identifies Endothelial Remodeling and Candidate VEGF‐Pathway Targets
BACKGROUND: Juvenile nasopharyngeal angiofibroma (JNA) is a rare locally aggressive vascular sinonasal tumor that primarily affects adolescent males. Despite advances in endoscopic surgery and preoperative embolization, JNA can be associated with major operative bleeding risk and clinically meaningful recurrence, while non-surgical treatment options remain limited. METHODS: To define the cellular programs underlying JNA vascularity, we performed single-cell RNA sequencing of post-embolization JNA tumors (n = 2), tumor-adjacent mucosa, and control sinonasal tissue. We analyzed cell composition, differential gene expression, pathway enrichment, and cell-cell communication, followed by Drug2cell-based mapping of transcriptional states to candidate therapeutic targets. RESULTS: JNA contained an expanded fibrovascular compartment composed of endothelial cells, fibroblasts, pericytes, vascular smooth muscle cells, and neuronal-like cells. Neuronal-like cells were enriched in JNA but showed relatively limited transcriptional differences from tumor-adjacent tissue. By contrast, endothelial cells demonstrated the strongest disease-associated remodeling, with enrichment of angiogenesis, extracellular matrix organization, hypoxia response, and cell migration pathways. Endothelial cells also showed downregulation of adaptive immune signaling pathways, suggesting reduced immune engagement within the tumor microenvironment. Intercellular communication analyses revealed dense endothelial-stromal signaling across the JNA fibrovascular network. Drug2cell analysis nominated VEGF/VEGFR signaling as a candidate drug target, with VEGFR-inhibiting agents predicted to act primarily on endothelial populations. CONCLUSIONS: JNA is organized around an angiogenesis-dominant fibrovascular program driven by endothelial-centered signaling. These data support further investigation of VEGF/VEGFR-directed inhibition as a potential adjunctive strategy for patients with recurrent, unresectable, or surgically high-risk JNA.
Authors
- FREDERIC ASKIN
- Hiroaki Murano (ORCID: https://orcid.org/0009-0002-3886-9951)
- Adam J. Kimple (ORCID: https://orcid.org/0000-0003-1670-8401)
- Brittany Rupp (ORCID: https://orcid.org/0000-0003-3654-9882)
- Lisa C. Morton (ORCID: https://orcid.org/0009-0000-3061-1652)
- Heidi Martini‐Stoica (ORCID: https://orcid.org/0000-0003-1599-9905)
- Brian D. Thorp (ORCID: https://orcid.org/0009-0008-9886-2317)
- Kevin M. Byrd (ORCID: https://orcid.org/0000-0002-5565-0524)
- Brent Anthony Senior (ORCID: https://orcid.org/0000-0002-1503-3150)
- Alessandra Livraghi-Butrico (ORCID: https://orcid.org/0000-0001-8751-3631)
- Jackson Ross Vuncannon (ORCID: https://orcid.org/0000-0003-0714-4747)
- Meik Kunz (ORCID: https://orcid.org/0000-0003-0385-2084)
- Charles S. Ebert (ORCID: https://orcid.org/0000-0002-8254-302X)
- Hong Dang
- Kenichi Okuda
- Minako Furusho
- Wanda O'Neal
- Scott Randell
- David A. Bader
- Cristine Klatt‐Cromwell
Institutions
- University of North Carolina at Chapel Hill (US)
- Duke University (US)
- Virginia Commonwealth University (US)
- Duke Medical Center (US)
- VCU Massey Comprehensive Cancer Center (US)
Publication Details
- Journal
- International Forum of Allergy & Rhinology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1002/alr.70310
- Primary Topic
- Head and Neck Surgical Oncology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chan Zuckerberg Initiative
- National Institutes of Health
- National Cancer Institute